PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.12%
Negative revenue growth while MCHP stands at 2.96%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-16.95%
Negative gross profit growth while MCHP is at 5.49%. Joel Greenblatt would examine cost competitiveness or demand decline.
-79.40%
Negative EBIT growth while MCHP is at 8.20%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-83.45%
Negative operating income growth while MCHP is at 6.56%. Joel Greenblatt would press for urgent turnaround measures.
-66.33%
Negative net income growth while MCHP stands at 4.06%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-66.18%
Negative EPS growth while MCHP is at 5.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-65.67%
Negative diluted EPS growth while MCHP is at 10.53%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.50%
Share reduction while MCHP is at 0.49%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.49%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
22.98%
Dividend growth above 1.5x MCHP's 0.18%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-9.73%
Negative OCF growth while MCHP is at 83.16%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-5.99%
Negative FCF growth while MCHP is at 98.11%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
103.30%
10Y revenue/share CAGR at 75-90% of MCHP's 136.60%. Bill Ackman would press for new markets or product lines to narrow the gap.
3.27%
5Y revenue/share CAGR under 50% of MCHP's 48.68%. Michael Burry would suspect a significant competitive gap or product weakness.
10.62%
3Y revenue/share CAGR under 50% of MCHP's 85.28%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
113.57%
10Y OCF/share CAGR above 1.5x MCHP's 58.19%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-6.01%
Negative 5Y OCF/share CAGR while MCHP is at 61.31%. Joel Greenblatt would question the firm’s operational model or cost structure.
20.95%
3Y OCF/share CAGR under 50% of MCHP's 120.12%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
165.64%
Net income/share CAGR at 75-90% of MCHP's 218.39%. Bill Ackman would press for strategic moves to boost long-term earnings.
-56.90%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-55.02%
Negative 3Y CAGR while MCHP is 234.54%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
49.55%
10Y equity/share CAGR at 50-75% of MCHP's 92.28%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
35.46%
5Y equity/share CAGR above 1.5x MCHP's 12.49%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
25.81%
Below 50% of MCHP's 90.30%. Michael Burry suspects a serious short-term disadvantage in building book value.
856.00%
Dividend/share CAGR of 856.00% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
109.92%
5Y dividend/share CAGR above 1.5x MCHP's 32.78%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
76.00%
3Y dividend/share CAGR above 1.5x MCHP's 3.04%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-24.21%
Firm’s AR is declining while MCHP shows 14.02%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.92%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-2.19%
Negative asset growth while MCHP invests at 2.07%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.41%
We have a declining book value while MCHP shows 2.05%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.07%
We’re deleveraging while MCHP stands at 0.48%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-8.21%
Our R&D shrinks while MCHP invests at 7.81%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-5.08%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.